Integrated PET-CT: Evidence-based review of oncology indications

ONCOLOGY

Volumn 19, Issue 4, 2005, Pages 481-490

  Sachelarie, Irina ^a   Kerr, Karolyn ^b   Ghesani, Munir ^c   Blum, Ronald H ^a,b,d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d Beth Israel Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; LYMPHOMA; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; EVIDENCE BASED MEDICINE; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLOGY; RADIOGRAPHY; SCINTISCANNING;

COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 23844525146     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Antoch G, Freudenberg LS, Stattaus J, et al: Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials. Am J Roentgenol 179:1555-1560, 2002.
2. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003.
3. Lardinois D, Steinen HC, Tutic M, et al: Incidence of non-metastatic extrathoracic lesions detected by whole-body FDG PET-CT imaging in patients with non-small-cell lung cancer (abstract 7186). Proc Am Soc Clin Oncol 23:659, 2004.
4. Buck A, Wahl A, Mueller N, et al: Utility of FDG-PET and FDG-PET-CT image fusion for the evaluation of suspicious pulmonary nodules - implications for staging of lung cancer (abstract 73). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
5. Antoch G, Stattaus J, Nemat AT, et al: Non-small cell lung cancer: Dual-modality PET-CT in preoperative staging. Radiology 229:526-533, 2003.
6. Schaffler GJ, Wolf G, Schoellnast H, et al: Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231:858-865, 2004.
7. Erdi YE, Rosenzweig K, Erdi AK, et al: Radiotherapy treatment planning for patients with non-small cell lung cancer using PET. Radiother Oncol 62:51-60, 2002.
8. Mah K, Caldwell CB, Ung YC, et al: The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Im J Radiat Oncol Biol Phys 52:339-350, 2002.
9. Wang Y, Yu J, Liu J, et al: PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis: Initial experience. Int J Radiat Oncol Biol Phys 57(suppl):S362-S363, 2003.
10. Fueger BJ, Quon A, Auerbach MA, et al: FDG-PET, PET-CT and software fusion: Diagnostic performance in re-staged breast cancer patients (abstract 246). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
11. Alberini JL, Collignon MA, Pichon MF, et al: PET-CT using FDG in diagnosis of recurrent breast carcinoma and its impact on patient management (abstract 245). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
12. Buck A, Wahl A, Eicher U, et al: Combined morphological and functional imaging with FDG PET-CT for restaging breast cancer: Impact on patient management (abstract 252). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
13. Tatsumi M, Cohade C, Mourtzikos K, et al: Initial experience with FDG PET-CT in the evaluation of breast cancer (abstract 1403). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
14. Kole AC, Plukker JT, Nieweg OE, et al: Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78:521-527, 1998.
15. 18F-FDG PET and PET-CT in patients with newly diagnosed esophageal carcinoma (abstract 63). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
16. Bar-Shalom R, Leiderman M, Gaitini D, et al: The value of PET-CT using FDG in patients with esophageal cancer (abstract 65). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
17. Antoch G, Kanja J, Bauer S, et al: Comparison of PET, CT, and dual-modality PET-CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357-365, 2004.
18. Burger I, Goerres GW, von Schulthess GK, et al: PET-CT diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225(suppl P):242, 2002.
19. 18F-FDG PET and PET-CT in patients with colorectal carcinoma. J Nucl Med 44:1797-1803, 2003.
20. Rosen RS, Patel PV, Wahl RL, et al: The role of FDG PET-CT in the initial staging of newly diagnosed and untreated colorectal cancer (abstract 1069). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
21. Even-Sapir E, Parag Y, Lerman H, et al: Detection of recurrence in patients with rectal cancer: PET-CT after abdominoperineal or anterior resection. Radiology 232:815-822, 2004.
22. Lemke AJ, Niehues SM, Hosten N, et al: Retrospective digital image fusion of multidetector CT and 18F-FDG PET: Clinical value in pancreatic lesions - a prospective study with 104 patients. J Nucl Med 45:1279-1286, 2004.
23. Tatsumi M, Cohade C, Mourtzikos K, et al: FDG-PET CT in evaluating patients with pancreatic cancer: Initial experience (abstract C24-417). 89th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, November 28-December 3, 2003. Available at http://rsna2003.rsna.org. Accessed March 2, 2005.
24. Kinkel K, Lu Y, Both M, et al: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 224:748-756, 2002.
25. Schaefer N, Hany T, Taverna C, et al: Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 232:823-829, 2004.
26. Mari C, Taur A, Vasanawala, et al: Evaluation of accuracy in staging and change in patient management in lymphoma. A comparative study between FDG PET, CT and PET-CT (abstract 256). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
27. Quon A, Allen-Auerbach M, Weber W, et al: FDG-PET, PET-CT, hardware fusion, software fusion: Comparison in lymphoma patients (abstract 255). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
28. Juweid ME, Wiseman G, Menda Y, et al: Integrated PET based response classification for non-Hodgkin's lymphoma (abstract 6533). Proc Am Soc Clin Oncol 23:563, 2004.
29. Goerres G, Schmid D, von Schulthess G, et al: FDG PET-CT improves the confidence of anatomic assignment of cancer lesions in the head and neck: A comparison with FDG PET and contrast enhanced CT (abstract 417). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
30. Syed R, Nagabhushan N, Hughes S, et al: Impact of combined PET-CT in head and neck tumors (abstract 420). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
31. Schoder H, Yeung HW, Gonen M, et al: Head and neck cancer: Clinical usefulness and accuracy of PET-CT image fusion. Radiology 231:65-72, 2004.
32. Koshy M, Paulino AC, Howell R, et al: The influence of F-18 FDG PET-CT fusion on radiotherapy treatment planning for head and neck cancer (abstract 5534). Proc Am Soc Clin Oncol 23:494, 2004.
33. Ciernik F, Dizendorf E, Baumert B, et al: Radiation treatment planning with an integrated PET-CT: A feasibility study. Int J Radiat Oncol Biol Phys 57:853-863, 2003.
34. Farsad M, Santagata F, Bellanova B, et al: 18F-FDG PET-CT in the follow-up of patients with thyroid cancer (abstract 1100). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
35. Palmedo H, Meyka S, Manka-Waluch A, et al: PET-CT for restaging of differentiated thyroid cancer: Coregistered imaging in comparison with PET alone (abstract 1104). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
36. Krausz Y, Guralnik L, Bettman L, et al: The incremental value of PET-CT over FDG-PET in the assessment of patients with differentiated thyroid cancer (abstract 540). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
37. Textor H, Reinhardt M, Jaeger U, et al: Combined FDG PET-CT imaging in patients with malignant melanoma: Initial results (abstract G24-739). 89th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, November 28-December 3, 2003. Available at http://rsna2003.rsna.org. Accessed March 2, 2005.
38. Romer W, Noemayr A, Greess H, et al: Retrospective fusion of F-18-FDG-PET and CT: Additional diagnostic information in melanoma patients (abstract 1139). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
39. Mottaghy FM, Blumstein NM, Dankerl A, et al: PET-CT for staging and restaging in malignant melanoma (abstract 1146). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
40. 18FDG-pet scanning in preoperative melanoma patients (abstract 7520). Proc Am Soc Clin Oncol 23:711, 2004.
41. Pannu H, Bristow R, Cohade C, et al: PET-CT detection of chest metastases from ovarian cancer (abstract K03-946). 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, December 1-6, 2002.
42. Bristow RE, del Carmen MG, Pannu HK, et al: Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET-CT. Gynecol Oncol 90:519-528, 2003.
43. Alberini JL, Sarandi F, Pichon MF, et al: Impact of PET-CT on treatment decision for patients with recurrent ovarian carcinoma (abstract 426). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
44. Heron D, Bhatnagar A, Blodgett T, et al: PET-CT in staging and re-staging patients with carcinoma of the uterine cervix (abstract Q13-1413). 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, December 1-6, 2002.
45. Israel O, Keidar Z, Bar-Shalom R, et al: Hybrid PET-CT imaging with FDG in management of patients with gynecologic malignancies (abstract 421). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
46. Cohade C, Tatsumi M, Mourtzikos K, et al: Initial experience in imaging endometrial carcinoma with FDG and PET-CT: Direct comparison with PET (abstract 423). 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, June 21-25, 2003.
47. Cook GJ, Houston S, Rubens R, et al: Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998.
48. Israel O, Militianu D, Golberg A, et al: PET-CT assessment of bone metastases-FDG avidity and CT patterns before and after treatment (abstract 224). 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, June 19-23, 2004.
49. 18F-fluoride PET-CT. J Nucl Med 45:272-278, 2004.
50. Patz EF, Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487-490, 1993.